PDF(Pubmed)
Abstract：
Chemotherapy has helped prolong survival in patients with malignant lymphoma, enhancing their quality of life (QOL). Despite the eventual decline in the QOL of patients, the impact of initial chemotherapy remains poorly understood. A prospective patient-reported QOL survey among patients with malignant lymphoma receiving initial chemotherapy was conducted, targeting those treated at Gifu Municipal Hospital (Gifu, Japan) between January 2021 and December 2022. Surveys were conducted pre- and post-chemotherapy based on the EuroQol 5 dimensions. Drug costs were calculated using official prices and analyzed from the cost payer\'s perspective via cost-utility analysis. Among the 60 patients included in the present study, 28 had diffuse large B-cell lymphoma. Cyclophosphamide, doxorubicin, vincristine, prednisolone ± rituximab therapy was the most common treatment (38 patients) and demonstrated superior cost-effectiveness due to its lowest cost and change in utility value. Initial chemotherapy for patients with malignant lymphoma generally improved the QOL. Clinical trial registration: UMIN000042868 (registered on December 28, 2020).
摘要：
化疗有助于延长恶性淋巴瘤患者的生存期，提高他们的生活质量（QOL）。尽管患者的生活质量最终下降，初始化疗的影响仍然知之甚少.在接受初始化疗的恶性淋巴瘤患者中进行前瞻性患者报告的QOL调查，针对在Gifu市政医院（Gifu，日本）2021年1月至2022年12月。基于EuroQol5维度进行化疗前后调查。使用官方价格计算药品成本，并通过成本效用分析从成本支付者的角度进行分析。在本研究纳入的60名患者中，28例弥漫性大B细胞淋巴瘤。环磷酰胺,阿霉素,长春新碱,泼尼松龙±利妥昔单抗治疗是最常见的治疗方法(38例患者),并且由于其最低的成本和效用值的变化而表现出优异的成本-效果.恶性淋巴瘤患者的初始化疗通常会改善QOL。临床试验注册：UMIN000042868（2020年12月28日注册）。
